LENSAR, Inc. (LNSR) stock
LNSRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/3022% below fair value
$4.85−0.06 (-1.22%)
Close on Nov 18, 2026Market cap $59.59MP/E –Yield –
Lensar r&d expenses
Research and development expenses are spending on new products and technology.
Lensar's R&D Expenses for the twelve months ending Jun 30, 2026 was $5.32M, down 3.2% year over year. For fiscal 2025 it was $5.62M, up 5.5% from the year before. The highest annual figure on record is $12.36M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.62M | +5.5% |
| FY2024 | Dec 31, 2024 | $5.33M | -13.2% |
| FY2023 | Dec 31, 2023 | $6.14M | -48.0% |
| FY2022 | Dec 31, 2022 | $11.81M | -4.4% |
| FY2021 | Dec 31, 2021 | $12.36M | +63.6% |
| FY2020 | Dec 31, 2020 | $7.55M | -0.2% |
| FY2019 | Dec 31, 2019 | $7.57M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.27M | -10.7% |
| Q1 FY2026 | Mar 31, 2026 | $1.39M | -9.7% |
| Q4 FY2025 | Dec 31, 2025 | $1.30M | -2.9% |
| Q3 FY2025 | Sep 30, 2025 | $1.37M | +13.7% |
| Q2 FY2025 | Jun 30, 2025 | $1.43M | +5.7% |
| Q1 FY2025 | Mar 31, 2025 | $1.53M | +6.2% |
| Q4 FY2024 | Dec 31, 2024 | $1.34M | -8.7% |
| Q3 FY2024 | Sep 30, 2024 | $1.20M | -21.3% |
| Q2 FY2024 | Jun 30, 2024 | $1.35M | -10.1% |
| Q1 FY2024 | Mar 31, 2024 | $1.44M | -12.5% |
| Q4 FY2023 | Dec 31, 2023 | $1.46M | -9.4% |
| Q3 FY2023 | Sep 30, 2023 | $1.53M | -3.2% |
| Q2 FY2023 | Jun 30, 2023 | $1.50M | -60.9% |
| Q1 FY2023 | Mar 31, 2023 | $1.65M | -65.5% |
| Q4 FY2022 | Dec 31, 2022 | $1.62M | -52.8% |
| Q3 FY2022 | Sep 30, 2022 | $1.58M | -50.5% |
| Q2 FY2022 | Jun 30, 2022 | $3.83M | +27.5% |
| Q1 FY2022 | Mar 31, 2022 | $4.79M | +74.4% |
| Q4 FY2021 | Dec 31, 2021 | $3.42M | +34.6% |
| Q3 FY2021 | Sep 30, 2021 | $3.18M | +58.8% |
| Q2 FY2021 | Jun 30, 2021 | $3.01M | +109.6% |
| Q1 FY2021 | Mar 31, 2021 | $2.75M | +74.8% |
| Q4 FY2020 | Dec 31, 2020 | $2.54M | +80.4% |
| Q3 FY2020 | Sep 30, 2020 | $2.01M | -53.7% |
| Q2 FY2020 | Jun 30, 2020 | $1.43M | – |
| Q1 FY2020 | Mar 31, 2020 | $1.57M | – |
| Q4 FY2019 | Dec 31, 2019 | $1.41M | – |
| Q3 FY2019 | Sep 30, 2019 | $4.33M | – |
See a number that looks wrong?